Industry News
August 2025
Fall Vaccine Updates

As we enter mid-fall and illnesses such as the influenza virus are on the rise, it is important to review the available vaccines, guidelines, and changes that have occurred. This guide will help consolidate key vaccine information into a single document for your reference and convenience as well as provide access to VIS and consent forms. Though this provides some general information, it is important to look at individualized patient needs and prescriber specific recommendations.

Flu Vaccine Recommendations

  • Everyone over the age of 6 months should receive a dose to be up to date.
  • Best time for vaccination is September/October.
  • All flu vaccines are trivalent formulation this year, inactivated, recombinant, live attenuated, along with High-Dose.
  • ACIP made a special off-label recommendation for people 18-64 with immunosuppression from organ transplant can now be given the High- Dose or adjuvanted flu vaccine which is typically indicated for ages 65+.

Flu (VIS)

Flu CPT/CVS Codes Product List

Respiratory Syncytial Virus (RSV)
Vaccine Recommendations

  • There are three currently available products.
  • This vaccine is not an annual vaccine like flu – it's a once single lifetime dose.
  • The newest vaccine Mresvia by Moderna is an mRNA vaccine, while the other two are recombinant.
  • The general recommendation is to give a single dose to all adults 60+.
  • A monoclonal antibody, Nirsevimab, is available for pediatric use for infants up to 8 months old going into their first RSV season.

RSV (VIS)

Pneumococcal Vaccine Recommendations

  • The age for routine vaccination has been lowered from 65 to 50 (PCV only).
  • Risk based recommendation still applies for individuals ages 19-49.
  • CDC approved use of the new PCV21 vaccine (Capvaxive) to be officially added to all pneumococcal recommendations.

Pneumococcal Conjugate Vaccine (VIS)
Pneumococcal Polysaccharide Vaccine (VIS)
Pneumococcal Vaccine Timing for Adults


COVID-19 Vaccine Recommendations

  • All individuals over the age of 6 months are eligible to receive a dose of the 2024-25 COVID-19 vaccine (pediatrics have more specific dosing based on prior vaccine history).
  • Adults over the age of 65, or individuals that are moderate to severely immunocompromised are now eligible to receive a 2nd dose of the 2024-25 formulation 6 months after the previous dose to be considered up to date.
  • An additional third dose can be considered based on shared clinical decision making for severely immunocompromised individuals with at least a two-month interval from last dose.
  • Reminder – moderate to severely compromised individuals dosing guidelines suggest that the initial dose series should be completed with the 2024-25 vaccine, meaning they will need the initial three-dose series and then the additional 4th dose after 6 months.